Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab phase 1/2 study in advanced solid tumors
NL-OMON60389Phase 2Recruiting
- Sponsor
- Merus
- Start
- May 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of petosemtamab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) (3 arms), sponsored by Merus. Primary endpoints: Objective response rate and Safety and tolerability. Started May 2023; status: recruiting.
02
Drugs
petosemtamab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON60389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60389.